Omnia Korani, Assistant Lecturer at the National Cancer Institute, shared a post on LinkedIn:

“Adjuvant pembrolizumab plus chemotherapy did not improve DFS in patients with newly diagnosed, high-risk, all-comer endometrial cancer. Preplanned subgroup analyses for stratification factors suggest that pembrolizumab plus chemotherapy improved DFS in patients with dMMR tumours. Safety was manageable.”

ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer

Authors: T. Van Gorp, D. Cibula, W. Lv, F. Backes, F. Ortaç, K. Hasegawa, K. Lindemann, A. Savarese, A. Laenen, Y.M. Kim, L. Bodnar, M.-P. Barretina-Ginesta, L. Gilbert, B. Pothuri, X. Chen, M.B. Flores, T. Levy, N. Colombo, C. Papadimitriou, T. Buchanan, L.C. Hanker, G. Eminowicz, L. Rob, D. Black, J. Lichfield, G. Lin, R. Orlowski, S. Keefe, A. Lortholary, B. Slomovitz on behalf of the ENGOT-en11/GOG-3053/KEYNOTE-B21 investigators.

Omnia Korani: Pembrolizumab plus chemotherapy did not improve DFS in high-risk endometrial cancer

Source: Omnia Korani/LinkedIn